SOUTH SAN FRANCISCO, Calif. & SEATTLE, September 07, 2022--(BUSINESS WIRE)--Sonoma Biotherapeutics, Inc., a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies for autoimmune and inflammatory diseases, today announced the appointment of Jessica Stitt as Chief Financial Officer. Stitt has over 20 years of healthcare finance, strategy, and leadership experience and has participated in the execution of nearly $2 billion in corporate financing transactions. She will join Sonoma Biotherapeutics’ executive leadership team and oversee the company’s finance, accounting, information technology, communications, and investor relations functions.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220907005587/en/

Jessica Stitt, Chief Financial Officer, Sonoma Biotherapeutics (Photo: Business Wire)

"Jessica is a healthcare industry veteran with a wealth of finance strategy and operations experience," said Jeff Bluestone, Ph.D., Co-founder and CEO of Sonoma Biotherapeutics. "She has a deep knowledge of capital markets and an impressive track record of financing clinical stage biotech companies. She’s joining the company at an exciting time as we move our therapies into the clinic and look toward our next phase of funding. She will play a critical role in our mission to bring durable therapies to patients suffering from chronic, debilitating autoimmune diseases. On behalf of the company and Board of Directors, I am thrilled to welcome Jessica to the team."

Prior to joining Sonoma Biotherapeutics, Stitt served as Chief Financial Officer at Gyroscope Therapeutics, a global clinical-stage gene therapy company focused on diseases of the eye, acquired by Novartis. Stitt previously served as Vice President of Finance and Operations for MyoKardia, Inc., acquired by Bristol Myers Squibb, and prior to that, served as Vice President of Finance and Investor Relations for Theravance Biopharma, Inc. She previously held roles in finance at Nektar Therapeutics, Alkermes, and Blue Cross Blue Shield of Massachusetts. Stitt holds an MBA from Simmons School of Management and a B.A. from Saint Anselm College.

"I am very excited to join the team that is leading the next frontier in cell therapy," said Stitt. "I was attracted to Sonoma Biotherapeutics for many reasons – passionate people, world-class science, and a mission to not just treat autoimmune and inflammatory diseases, but potentially cure them, with one-time living therapies. I look forward to doing my part to steer the company through its next phase of growth, funding, and clinical milestones."

Sonoma Biotherapeutics is a clinical-stage biotechnology company developing engineered regulatory T cell (Treg) therapies to treat serious autoimmune and inflammatory diseases by restoring balance to the immune system. Founded by pioneers in Treg biology and cell therapy, the company is employing proprietary platform technologies and approaches to develop a new generation of targeted and durable Treg cell therapies designed to cure autoimmune and inflammatory diseases. Sonoma Biotherapeutics is based in South San Francisco and Seattle. For more information visit sonomabio.com and follow on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220907005587/en/

Brian Crawford Sonoma Biotherapeutics bcrawford@sonomabio.com 650-238-7876

Jason Spark Evoke Canale Jason.spark@evokegroup.com 619-849-6005

Nio (NYSE: NIO) reported increasing losses in its second-quarter earnings report this week, but investors are shrugging that off, sending shares soaring Friday morning. Although its profit margins have been on a downward trend, new models being launched could turn that around in the coming years. Consumer prices in China increased at a slower pace than many expected in August, and producer inflation sank to the lowest level since February 2021, reports Reuters.

As we close in on the final quarter of 2022, investors are looking for an answer to one question: was June’s low the bottom for stocks, or do they have more room to fall? It’s a serious question, and there may be no easy answer. Markets are facing a series of headwinds, from the high inflation and rising interest rates that we’ve grown familiar with to an increasingly strong dollar that will put pressure on the upcoming Q3 earnings. Weighing in on current conditions from Charles Schwab, the $8 t

Berkshire Hathaway is on pace to collect $6.07 billion in dividend income over the next 12 months. Just five holdings will account for 71% of total payouts.

Peloton Interactive (NASDAQ: PTON) shares beat the market on Friday as the stock gained 11% by 1 p.m. ET compared to a 1.2% increase in the S&P 500. Shares have been reeling in recent months as Peloton struggled to boost sales of its exercise platforms or membership subscriptions to its services.

Advanced Micro Devices, Inc. stock is trending on the Yahoo Finance Platform. Here is a visualization of $AMD performance over time, how that performance compares to the wider industry, and analyst projections for the current quarter.Check out the ticker page here.

The S&P 500 is on again, off again all year. But investors clearly have a "buy list" of stocks they want to own when the rally looks real.

Investors are seeing higher growth potential for QuantumScape's battery cell technology after an interesting EV industry development.

Recently, Zacks.com users have been paying close attention to AT&T (T). This makes it worthwhile to examine what the stock has in store.

A strong bearish trend defined the markets in the first half of the year; since then, the key point has been volatility. Stocks hit a bottom back in June, when the S&P 500 dropped into the 3,600s. That has proven to be a support level in the last two months, and at least one strategist believes that the market won’t be testing those lows again this year. JPMorgan's Jason Hunter believes that inflation may have peaked, and that the upcoming CPI report will provide additional evidence of that. “We

In this article, we will look at 10 stocks that Jim Cramer is talking about in September. If you want to explore more stocks that journalist investor, Jim Cramer, is talking about in September, you can also take a look at Jim Cramer is Talking About These 5 Stocks in September. Jim Cramer has acquired […]

FuelCell Energy (FCEL) posts wider-than-expected fiscal Q3 loss. FCEL's backlog remains strong and the company continues to deliver modules and meet customer needs through clean energy generation.

In this article, we discuss 10 dividend stocks with over 8% yield to buy in September. You can skip our detailed analysis of top high dividend stocks, and go directly to read 5 Best Dividend Stocks with Over 8% Yield You Can Buy in September. In the current market situation, investors are looking for different […]

Gary Gensler had strong words for the crypto industry in a Thursday speech, telling an audience of lawyers that the "vast majority" of the nearly 10,000 existing crypto tokens are securities.

On Friday, the company unveiled the Robinhood Investor Index, which captures how customers invest based on the top 100 most owned stocks on the platform.

See how to gauge demand and strength in Apple, Nasdaq and other stocks on the latest list of new buys by the best mutual funds.

AT&T income-hungry shareholders should have seen it coming. In April last year, a month before announcing the spinoff of its media division to shareholders in the form of shares of a 71% stake in the newly created Warner Bros. Discovery Chief Executive Officer John Stankey assured investors that “our deliberate capital-allocation plan allowed us to invest and sustain our dividend at current levels, which we believe is attractive.” AT&T’s eventual failure to raise the dividend in 2021 broke a 34-year streak and saw it booted out of the vaunted S&P 500 Dividend Aristocrats Index.

Pinterest (PINS) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

A couple of catalysts drove the crypto trading specialist higher, including an upgrade by a Wall Street analyst and news it plans to fund a court battle challenging a U.S. Treasury Department decision. Daiwa analyst Carlton Lai upgraded Coinbase to buy from outperform (weak buy), while maintaining his price target of $100. Furthermore, after "years of delay," he views the upcoming debut of Ethereum's (CRYPTO: ETH) The Merge as "one of the crypto industry's biggest events this year."

The old saying “different strokes for different folks” certainly rings true in the stock market. Some investors prefer growth stocks like Tesla Inc. that are volatile but have produced years of outstanding appreciation. Other folks prefer less volatile stocks like Johnson & Johnson whose growth may be slower but also add dividends of 2% to 3% annually to the total performance. In addition, there are income investors, who strictly look for stocks that will provide high-yield dividends year after

FuboTV's (FUBO) leading live sports TV streaming platform, Fubo Gaming, announces the launch of its Sportsbook in New Jersey via an agreement with Caesars Entertainment Inc.